Trials / Active Not Recruiting
Active Not RecruitingNCT04530916
Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women
Antihypertensive and Vascular-Protective Effects of Wild Blueberries in Middle-Aged/Older Men and Postmenopausal Women.
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Colorado State University · Academic / Other
- Sex
- Male
- Age
- 45 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Aging is the primary risk factor for CVD, in large part due to adverse modifications to the arteries. These modifications include vascular endothelial dysfunction and arterial stiffness. Vascular endothelial dysfunction is an initiating step in atherosclerosis, and is primarily caused by reduced nitric oxide (NO) bioavailability secondary to excessive superoxide-driven oxidative stress and inflammation. Endothelial dysfunction leads to arterial stiffness and the development of hypertension (HTN) which further increases CVD. Greater than 2/3 of the US population has elevated blood pressure or stage 1-HTN. As such, interventions that improve vascular endothelial dysfunction by increasing NO bioavailability and mitigating excessive oxidative stress and inflammation are needed. Blueberries are rich in bioactive compounds including flavonoids, phenolic acids, and pterostilbene. These compounds and their metabolites have been shown to attenuate oxidative stress and inflammation. The primary goal of this study is to assess the efficacy of blueberries to improve reduce blood pressure and improve vascular endothelial dysfunction and arterial stiffness in middle-aged/older men with elevated blood pressure or stage 1-HTN.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Blueberry Powder | 22 g/day wild blueberry powder |
| DIETARY_SUPPLEMENT | Placebo Powder | 22 g/day placebo powder |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2025-03-31
- Completion
- 2025-12-31
- First posted
- 2020-08-28
- Last updated
- 2025-11-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04530916. Inclusion in this directory is not an endorsement.